SIGN IN
This site is for Healthcare Professionals only | Consumer Site
Visit ZyrtecProfessional.com for additional allergy management information and products.

RHINOCORT® Allergy Spray effectively relieves patients' allergy symptoms

In seasonal allergic rhinitis (SAR), RHINOCORT® Allergy Spray provided significant relief of nasal symptoms vs placebo1

Mean change from baseline in Nasal Index Score (NIS) for 64 µg and 128 µg once daily in adults and children 6*1

RHINOCORT® Seasonal Allergic Rhinitis Treatment Efficacy RHINOCORT® Seasonal Allergic Rhinitis Treatment Efficacy RHINOCORT® Seasonal Allergic Rhinitis Treatment Efficacy

* Randomized, double-blind, parallel-group study of 406 patients. Patients received intranasal budesonide pump spray (RHINOCORT® Allergy Spray) 32 µg, 64 µg, 128 µg, or placebo once daily for 4 weeks. Graph depicts data for 64 µg and 128 µg doses. Nasal Index Score (NIS), the sum of nasal congestion, runny nose, and sneezing, was evaluated daily.

RHINOCORT® Allergy Spray provides significant improvements in perennial allergic rhinitis (PAR) symptoms2,3

RHINOCORT® Allergy Spray provides significant symptom relief all day and all night at 128 µg/day vs placebo†2,3

RHINOCORT® Perennial Allergic Rhinitis Treatment Efficacy RHINOCORT® Perennial Allergic Rhinitis Treatment Efficacy RHINOCORT® Perennial Allergic Rhinitis Treatment Efficacy

Randomized, placebo-controlled study conducted at multi-centers. Adult patients with PAR received either RHINOCORT® 128 μg (n=107) or placebo (n=104) once daily. Each morning and evening the patient recorded the severity of the nasal symptoms as evaluated by NIS (blocked nose, runny nose, itchy nose/sneezing) during the previous 12 hours in separate diaries. At week 4, the sum of these three variables (Nasal Index Score, NIS) was calculated.

References:

  1. Creticos P, Fireman P, Settipane G, Bernstein D, Casale T, Schwartz H; on behalf of the Rhinocort Aqua Study Group. Intranasal budesonide aqueous pump spray (Rhinocort® Aqua) for the treatment of seasonal allergic rhinitis. Allergy Asthma Proc. 1998;19(5):285-294.
  2. Data on file, Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division.
  3. Bende M, Carrillo T, Vóna I, da Castel-Branco MG, Arheden L. A randomized comparison of the effects of budesonide and mometasone furoate aqueous nasal sprays on nasal peak flow rate and symptoms in perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2002;88(6):617-623.